Massachusetts General Hospital Academy

The Virtual Grand Rounds Series provides your institution with consistent, high-quality, one-hour educational programs, presented by the Massachusetts General Hospital Psychiatry Academy’s world-renowned faculty. Led by Program Directors Jerrold F. Rosenbaum, MD, Psychiatrist in Chief at Massachusetts General Hospital, and Maurizio Fava, MD, Executive Vice Chair of the Psychiatry Dept. at Massachusetts General Hospital, the Virtual Grand Rounds Series allows doctors, residents, and medical students to conveniently acquire knowledge about clinical challenges and innovative treatment options for a variety of psychiatric disorders. Given the time constraints of today's clinical practice, the online format of the Virtual Grand Rounds Series means your medical staff can participate in real-time or choose to view the archived version whenever time allows. When viewed in live format, interactive features are enabled that let program faculty provide live feedback to questions and communicate directly with you and your staff.

Date	Grand Rounds	Learning Objectives
9/7/2011	Adjunctive Therapies in the Treatment of Schizophrenia: For Whom and For What? Donald C. Goff, MD	Recognize the relative evidence for efficacy of common adjunctive agents. Formulate an approach to the treatment resistant patient with schizophrenia. Identify specific adjunctive agents.
9/21/2011	Cognitive-Behavioral Therapy Susan Sprich, PhD and Timothy J. Petersen, PhD	Describe fundamental principles of CBT. Explain strategies for engaging patients in this treatment. Identify ways to conceptualize a common psychiatric disorder using a CBT framework.
10/5/2011	Neurosurgical Treatments for Psychiatric Illness Darin D. Dougherty, MD	Explain the efficacy and safety profile of vagus nerve stimulation for treatment resistant depression. Review the use of transcranial magnetic stimulation for the treatment of depression. Recognize the use of deep brain stimulation for intractable psychiatric illness.
10/19/2011	Treatment Resistant Depression George Papakostas, MD	Describe evidenced based polypharmacy strategies (augmentation and combination) for antidepressant partial- and non-responders with MDD. Identify monotherapy strategies (dose increase and switching) for antidepressant partial- and non-responders with MDD. Describe factors which help guide treatment selection in this population.
11/2/2011	Challenges Remain in the Diagnosis of Pediatric Bipolar Disorder Janet R. Wozniak, MD	Recognize that the diagnosis of pediatric bipolar disorder can be complicated by its developmentally distinct clinical presentation and complicated comorbidity. Review the emerging family genetic and longitudinal course evidence supporting the validity of the diagnosis of pediatric bipolar disorder. Identify the mood stabilizers used in the treatment of pediatric bipolar disorder.
11/16/2011	Treatment of Mood Disorders During Pregnancy: Lessons from Two Decades Lee S. Cohen, MD	Review data on the course of psychiatric disorders during pregnancy and postpartum. Recognize the risks of psychotropic drug use during pregnancy versus risk of untreated maternal psychiatric illness. Identify the relative risk of older versus newer antidepressants when used during pregnancy and the relative risks of psychiatric relapse following discontinuation of agents such as mood stabilizers or antidepressants.
11/30/2011	Acupuncture and Cranial Electrical Stimulation (CES) in Psychiatry David Mischoulon, MD	To understand the current evidence for acupuncture treatment of depression. To understand the current evidence for cranial electrical stimulation for various psychiatric disorders. To understand proposed mechanisms of action for the above treatments.
12/14/2011	The Heavy Burden of Psychiatric Comorbidity Associated with Autism Spectrum Disorders Gagan Joshi, MD	Recognize the significant presence of autism spectrum disorders (ASD) in psychiatrically referred populations Explain the heavy burden of psychiatric comorbidity in individuals with ASD. Identify the neural abnormalities associated with ASD.

• 
  Robert J. Birnbaum, MD, PhD
  Senior Education Research & Development Specialist, Post Graduate Medical Education, MGH
  Assistant Professor of Psychiatry, Harvard Medical School
• 
  Maurizio Fava, MD
  Executive Vice Chair, Department of Psychiatry, MGH
  Executive Director, Clinical Trials Network & Institute (CTNI), MGH
  Director, Depression Clinical & Research Program, MGH
  Slater Family Professor of Psychiatry, Harvard Medical School
• 
  John A. Fromson, MD
  Co-Director, MGH Postgraduate Medical Education
  Assistant Clinical Professor of Psychiatry, Harvard Medical School
• 
  Tristan L Gorrindo, MD
  Co-Director, MGH Postgraduate Medical Education
  Instructor in Psychiatry, Harvard Medical School
• 
  Jerrold F. Rosenbaum, MD
  Psychiatrist in Chief, Massachusetts General Hospital
  Stanley Cobb Professor of Psychiatry, Harvard Medical School
• Anan Natif, EdM
  Operations Director
  Postgraduate Medical Education
  Massachusetts General Hospital
  

Release Date: September 7, 2011

Expiration Date: December 14, 2012

To receive credit for this activity, listen to the presentation and complete the post-test and activity evaluation.

Accreditation Statement
This activity has been planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education (CME) for physicians.

McLean Hospital designates this enduring material for a maximum of 8 AMA PRA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Credit Designation

Psychologists: The Massachusetts General Hospital, Department of Psychiatry, is approved by the American Psychological Association to offer Continuing Education (CE) for psychologists and maintains responsibility for this program. This offering meets the criteria for 1 Continuing Education (CE) credit per presentation for psychologists.

 

Nurses: This program meets the requirements of the Massachusetts Board of Registration in Nursing (224 CMR 5.00) for 1 contact hour of nursing continuing education credit per presentation.

 

Social Workers: This program has been approved for 1 Social Work Continuing Education hour for relicensure, in accordance with 258 CMR. Collaborative of NASW and the Boston College and Simmons Schools of Social Work Authorization Number D51021.

Policy on Faculty and Provider Disclosure
It is the policy of McLean Hospital that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. Partners HealthCare System has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.

Planner Disclosures

The following planners of this activity have indicated that neither they nor their spouse/partner have a relevant financial relationship to disclose:

Jerrold F. Rosenbaum, MD, PhD:

John Fromson, MD, reviewer

Tristan Gorrindo, MD 

Robert Birnbaum, MD

Anan Nathif, EdM

The following planner of this activity has indicated that he or a member of his immediate family has a significant financial interest or affiliation with the manufacturer of a commercial product or provider of a commercial service which may affect the content of this presentation.  These disclosures may be germane to the content of the activity.

Maurizio Fava, MD

Advisory Board/Consulting:

Abbott Laboratories; Affectis Pharmaceuticals AG; Alkermes, Inc.; Amarin Pharma Inc.; Aspect Medical Systems; AstraZeneca; Auspex Pharmaceuticals; Bayer AG; Best Practice Project Management, Inc.; BioMarin Pharmaceuticals, Inc.; Biovail Corporation; BrainCells Inc; Bristol-Myers Squibb; CeNeRx BioPharma; Cephalon, Inc.; Clinical Trials Solutions, LLC; CNS Response, Inc.; Compellis Pharmaceuticals; Cypress Pharmaceutical, Inc.; DiagnoSearch Life Sciences (P) Ltd.; Dinippon Sumitomo Pharma Co. Inc.; Dov Pharmaceuticals, Inc.; Edgemont Pharmaceuticals, Inc.; Eisai Inc.; Eli Lilly and Company; ePharmaSolutions; EPIX Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Fabre-Kramer Pharmaceuticals, Inc.; Forest Pharmaceuticals, Inc.; GenOmind, LLC; GlaxoSmithKline; Grunenthal GmbH; i3 Innovus/Ingenis; Janssen Pharmaceutica; Jazz Pharmaceuticals, Inc.; Johnson & Johnson Pharmaceutical Research & Development, LLC; Knoll Pharmaceuticals Corp.; Labopharm Inc.; Lorex Pharmaceuticals; Lundbeck Inc.; MedAvante, Inc.; Merck & Co., Inc.; MSI Methylation Sciences, Inc.; Naurex, Inc.; Neuronetics, Inc.; NextWave Pharmaceuticals; Novartis AG; Nutrition 21; Orexigen Therapeutics, Inc.; Organon Pharmaceuticals; Otsuka Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; PharmaStar; Pharmavite® LLC.; PharmoRx Therapeutics; Precision Human Biolaboratory; Prexa Pharmaceuticals, Inc.; Puretech Ventures;  PsychoGenics; Psylin Neurosciences, Inc.; Rexahn Pharmaceuticals, Inc.; Ridge Diagnostics, Inc.; Roche; RCT Logic, LLC; Sanofi-Aventis US LLC.; Sepracor Inc.; Servier Laboratories; Schering-Plough Corporation; Solvay Pharmaceuticals, Inc.; Somaxon Pharmaceuticals, Inc.; Somerset Pharmaceuticals, Inc.; Sunovion Pharmaceuticals; Synthelabo; Takeda Pharmaceutical Company Limited; Tal Medical, Inc.; Tetragenex Pharmaceuticals, Inc.; TransForm Pharmaceuticals, Inc.; Transcept Pharmaceuticals, Inc.; Vanda Pharmaceuticals, Inc.

Speaking/Publishing:

Adamed, Co; Advanced Meeting Partners; American Psychiatric Association; American Society of Clinical Psychopharmacology; AstraZeneca; Belvoir Media Group; Boehringer Ingelheim GmbH; Bristol-Myers Squibb; Cephalon, Inc.; CME Institute/Physicians Postgraduate Press, Inc.; Eli Lilly and Company; Forest Pharmaceuticals, Inc.; GlaxoSmithKline; Imedex, LLC; MGH Psychiatry Academy/Primedia; MGH Psychiatry Academy/Reed Elsevier; Novartis AG; Organon Pharmaceuticals; Pfizer Inc.; PharmaStar; United BioSource,Corp.; Wyeth-Ayerst Laboratories

Research Support:

Abbott Laboratories; Alkermes, Inc.; Aspect Medical Systems; AstraZeneca; BioResearch; BrainCells Inc.; Bristol-Myers Squibb; Cephalon, Inc.; CeNeRx BioPharma; Clinical Trials Solutions, LLC; Clintara, LLC; Covidien; Eli Lilly and Company; EnVivo Pharmaceuticals, Inc.; Euthymics Bioscience, Inc.; Forest Pharmaceuticals, Inc.; Ganeden Biotech, Inc.; GlaxoSmithKline; Icon Clinical Research; i3 Innovus/Ingenix; Johnson & Johnson Pharmaceutical Research & Development; Lichtwer Pharma GmbH; Lorex Pharmaceuticals; NARSAD; NCCAM; NIDA; NIMH; Novartis AG; Organon Pharmaceuticals; PamLab, LLC.; Pfizer Inc.; Pharmavite® LLC; Photothera; Roche; RCT Logic, LLC; Sanofi-Aventis US LLC; Shire; Solvay Pharmaceuticals, Inc.; Synthelabo; Wyeth-Ayerst Laboratories

Stock/Other Financial Options:

Compellis Pharmaceuticals

Royalty/patent, other income:

Patent for SPCD and patent application for a combination of azapirones and bupropion in MDD, copyright royalties for the MGH CPFQ, SFI, ATRQ, DESS, and SAFER. Patent for research and licensing of SPCD with RCT Logic; Lippincott, Williams & Wilkins; World Scientific Publishing Co., Pte.Ltd

---

We are committed to giving learners the most comprehensive view of disclosure information. For this reason, in addition to listing the disclosures specific to this activity, we also maintain a database of global disclosures for all faculty who plan or speak at our activities. Biographical information for each facutly is also included. To view a specific speaker or planner’s global disclosure, please click on the appropriate link below.

Robert J. Birnbaum, MD, PhD

Maurizio Fava, MD

John A. Fromson, MD

Tristan L Gorrindo, MD

Anan Natif, EdM

Jerrold F. Rosenbaum, MD

 

---

 

Hardware/Software Specifications: 

 

This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.

Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher

Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bit

 

---

 

online